All In Biotech

Drug Trial Radar · NCT07425808

FLT3-ITD Targeted Therapy in Fit AML Patients

Gilteritinib in Combination With Azacitidine and Venetoclax Compared to Induction Chemotherapy "7+3" in Combination With a FLT3-inhibitor in Fit, Newly Diagnosed, FLT3-ITD Mutated Adult AML Patients: a Randomized Trial of the EORTC Leukemia Group and GIMEMA.

Last checked: Nov 19, 2026Latest source record: Feb 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 230 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

230

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Oct 1, 2028

Study completion Feb 1, 2032

Sponsor

Sponsor type
Research network
Collaborators
Fondazione GIMEMA; Astellas Pharma Inc
First posted
Feb 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This international, multicenter, randomized (1:1), open-label phase II/III trial will evaluate the efficacy and safety of gilteritinib combined with azacitidine and venetoclax (experimental arm) versus standard "7+3" induction plus a FLT3inhibitor (quizartinib or midostaurin) (control arm) in newly diagnosed FLT3-ITD mutated AML patients eligible for intensive chemotherapy.

Conditions

  • AML (Acute Myeloid Leukemia)

Interventions

  • GilteritinibDrug

    Cycle 1: 80 mg once daily orally on days 1-28. Cycle 2 - 12: 80mg once daily orally on days 1-28. Cycle 13 - 24: gilteritinib 120 mg once daily orally on days 1-28. Following HSCT, maintenance with gilteritinib (120 mg once daily orally on days 1-28) will be offered for up to 36 cycles and started between day 30 and 90 after hematopoietic stem-cell transplantation (HSCT).

  • VenetoclaxDrug

    Cycle 1: ramp-up from 100mg on day 1, 200 mg on day 2 and 400 mg on days 3 - 28. Cycle 2 - 12: venetoclax 400 mg once daily orally days 1-7.

  • Azacitidine (AZA)Drug

    Cycle 1: 75 mg/m² once daily subcutaneously on days 1-7. Cycle 2 -12: 75 mg/m² once daily subcutaneously on days 1-5. Cycle 13 - 24: 75 mg/m² once daily subcutaneously on days 1-5.

  • Local standard of care (SOC)Drug

    Local SOC is "7+3" + Midostaurin (100 mg) or Quizartinib (35.4 mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase II: Achievement of CR/CRi documented within 6 months from randomization, occurring prior to allografting and before initiation of any post-protocol treatments.Time frame: Within 6 months from randomization
  2. Phase III: Overall survivalTime frame: From baseline through study completion, an average of 7 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.